Barclays Upgrades Alvotech Following Successful FDA Inspection

Key Facts

1Barclays upgraded Alvotech stock after the company's manufacturing facility in Iceland received a Voluntary Action Indicated (VAI) classification from the U.S. FDA.

2The regulatory classification clears the path for approvals of several biosimilar products, including AVT05, AVT06, and AVT16, expected in late 2026 and early 2027.

In a move reflecting renewed optimism in the biosimilars sector, Barclays upgraded Alvotech stock following a successful U.S. FDA inspection of the company’s manufacturing facility in Iceland. The site received a Voluntary Action Indicated (VAI) classification, effectively removing a major regulatory overhang that had previously weighed on investor sentiment. According to reports, this regulatory clearance paves the way for the approval of key biosimilar products, including AVT05, AVT06, and AVT16, expected between late 2026 and early 2027.

This positive shift follows a period of financial scrutiny where analysts previously cited concerns regarding the company's leverage and high R&D expenditures. Per market data, Alvotech (ALVO) shares closed at $5.05 on September 14, 2026, while Barclays (BCS) closed at $25.86 on the same date. The upgrade reflects growing confidence in the company's efforts to strengthen quality systems and manufacturing operations at its Reykjavik plant.

Looking ahead, traders are monitoring final product approval decisions in the fourth quarter of 2026 as primary growth catalysts. ALVO stood at $5.05 (close September 14, 2026) with a session high of $5.26, establishing a near-term resistance level. With no major pharmaceutical-specific events in the upcoming economic calendar, market focus remains on the FDA’s timeline for the anticipated biosimilar launches.